Sincerity Pharmaceuticals: 4 drugs are planned to be selected for continuation of national centralized procurement.

Chengyi Pharmaceutical announced that the company has participated in the follow-up purchase of the varieties with expired agreements in the first to eighth batches of national centralized procurement. Glucosamine hydrochloride capsules, torasemide injection, lidocaine hydrochloride injection, and levocarnitine injection are planned to be selected, and the procurement period will last until December 31, 2028. In 2024, the revenue of glucosamine hydrochloride capsules, torasemide injection, and lidocaine hydrochloride injection were 334.89 million yuan, 6.5473 million yuan, and 0.1298 million yuan respectively; in the first three quarters of 2025, the revenue of the above products and levocarnitine injection were 345.3665 million yuan, 4.1982 million yuan, 0.1813 million yuan, and 0.1797 million yuan. The public notice period for the planned selection results will last until February 12, and the final results and their impact on the company are currently uncertain.